Iovance Biotherapeutics, Inc. Common Stock Wells Fargo 21st Annual Healthcare Conference

Thanks for having us. Our pleasure.

Sure. Our company is based on a therapy called TIL therapy, which is essentially taking immune cells that the body deems the most important to fight against the tumor, but there is just not enough of them out of the patient. We manufacture those to the billions, and then we prep the patient ahead of time, give those same cells that came from the patient, that are actually unmodified, right back to the patient. This therapy style has been around for decades. There are patients who are alive with refractory melanoma over 30 years since their treatment. We are building on the shoulder of giants. We are also based on a registrational trial that completed its five-year study. It has been published and really unprecedented long-term outcomes for these patients.

Absolutely. I will probably boil it down to a few things. I would say, just to remind everyone, we have a growing body of real-world evidence, which is showing response rates over 50% in true second line. I think having that communication with the physicians, them having that data, is giving them even more confidence to treat and to treat earlier. We have done some surveys, and our physician awareness over the past year has grown threefold. We have also grown our network of authorized treatment centers, so we have breadth as well as depth, and we are continuing to do so. We have mentioned before we will have at least 110 authorized treatment centers by the end of the year.

Yep. I won't guide for the third quarter, but let me tell you this. We're continuing to see those positive demand trends. And they're happening as we sit here, which is actually really, really good news as they continue to grow. As far as our forecast, we have mentioned that we will update our full year guidance. That'll give you a view into the full second half, Q3 and Q4, and we'll do that within this quarter. We mentioned that at the call.

I'll go back to an earlier comment. It's early days on the fourth quarter. We do have visibility because of the process. We are continuing to see positive demand trends. That's what I can tell you about the fourth quarter. And when we give that guidance, we'll have even a little bit more visibility, right? Not full, but we'll have a good sense of what's going on. But the positive demand trends are a good indicator.

Yes, that's the goal. I believe you will see quarter-over-quarter growth. Now, I do have to give one caveat. The first quarter and second quarter had a little bit of timing offset, so that growth percentage might be a little bit inflated because of the timing of some maintenance we did in the first quarter, but you will definitely be seeing growth.